Search

Your search keyword '"I V, Greshnova"' showing total 3 results
Start Over Author "I V, Greshnova"
3 results on '"I V, Greshnova"'

1. Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia

Author

A. N. Boiko, K. Z. Bakhtiyarova, M. A. Sherman, Z. A. Goncharova, I. V. Smagina, T. I. Khaibullin, N. N. Babicheva, N. N. Spirina, I. A. Yampolskaya-Gosteva, I. A. Sokolova, I. V. Greshnova, V. E. Nikitenkova, I. G. Lukashevich, A. V. Inzhinova, N. A. Malkova, D. S. Korobko, O. V. Boyko, and I. S. Lozovskaya

Subjects
multiple sclerosis, treatment, highly active multiple sclerosis, the quality of life, Neurology. Diseases of the nervous system, RC346-429
Abstract

Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative disease of the central nervous system. Now 2.8 million people in the world suffer from MS, since 2000 every 5 years there has been an increase in the number of MS patients by 10%. At the same time, the number of cases with highly active MS (HAMS) is increasing, i.e. cases of MS with two or more exacerbations without taking specific pathogenetic therapy or one exacerbation during taking MS disease-modifying therapies (DMTsMS), which is accompanied by the corresponding MRI data of the brain and spinal cord (presence of new or active lesions). Previously, there were no studies of quality of life (QoL) in this subgroup of patients in the world.Objective: to compare the QoL indicators of patients with HAMS with those of healthy people and patients with a typical course of relapsingremitting MS (RRMS).Patients and methods. The study included data on 518 patients from 14 regions of the Russian Federation for 2020–2021 years, in whom HAMS was confirmed during a second examination. We used the results of the analysis of clinical data from neurologists and data from questionnaires filled out by patients with HAMS. Two questionnaires were used in the work – the general (non-specific) Questionnaire for assessing the QoL, SF-36 (The MOS 36-item Short-Form Health Survey) and a special questionnaire for MS patients – MusiQoL (Multiple sclerosis Quality of Life).Results and discussion. Almost all indicators of QoL in HAMS were below the control. When compared with the typical course of RRMS, a more pronounced decrease in daily activity indicators, a significant impact of clinical symptoms on QoL, a negative attitude of patients towards the healthcare system, and a low overall health index were noted. Pearson correlation analysis revealed a stronger effect on QoL parameters of the frequency of exacerbations in HAMS than in RRMS.Conclusion. The data obtained in the study indicate the need for more active management of patients with HAMS using second-line DMTsMS.

Published
2022
Full Text
View/download PDF

2. [Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists]

Author

N N Spirin, F A Habirov, I. V. Greshnova, N A Malkova, Ya. V. Vlasov, A N Boyko, S A Sivertseva, Kotov Sv, I. A. Yampolskaya-gosteva, M. A. Bakalova, G N Belskaya, Ekaterina Popova, O. V. Boyko, E. I. Ivashinenkova, T. N. Gromova, M. A. Kurapov, M. V. Churakov, and T. I. Haybullin

Subjects
medicine.medical_specialty, Public organization, Multiple Sclerosis, Disabled people, Primary Progressive Multiple Sclerosis, Social issues, Russia, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Medicine, Humans, In patient, 030212 general & internal medicine, Neurologists, business.industry, Multiple sclerosis, virus diseases, Multiple Sclerosis, Chronic Progressive, medicine.disease, Psychiatry and Mental health, Family medicine, Sociology, Medical, Russian federation, Neurology (clinical), business, geographic locations, 030217 neurology & neurosurgery
Abstract

The main results of a medical-sociological study aimed at the evaluation of the level of satisfaction with treatment in patients with primary progressive multiple sclerosis (PPMS) are presented. The survey was conducted in 19 regions of the Russian Federation and involved 437 patients with confirmed diagnosis of PPMS and 80 neurologists specialized in multiple sclerosis. The research was carried out by the All-Russian Public Organization of Disabled People with Multiple Sclerosis with the participation of the Russian Committee for Treatment and Research in Multiple Sclerosis. This is the first medical-sociological study in the Russian Federation involving patients with PPMS and neurologists. The study revealed typical medical and social problems patients with PPMS faced. A significant decrease in quality-of-life of PPMS patients was shown.Представлены основные результаты медико-социологического исследования, проведенного с целью изучения уровня удовлетворенности терапией пациентов с первично-прогрессирующим рассеянным склерозом (ППРС). В опросе, проведенном в 19 регионах Российской Федерации, приняли участие 437 пациентов с установленным диагнозом ППРС и 80 неврологов, специализирующихся в области данного заболевания. Исследовательский проект был осуществлен Общероссийской общественной организацией инвалидов - больных рассеянным склерозом (ОООИБРС) при научном участии Российского комитета исследователей рассеянного склероза (РОКИРС). Это первый опыт проведения медико-социологического исследования на территории РФ, охватывающий и больных ППРС, и неврологов. Выявлены типичные медицинские и социальные проблемы, с которыми сталкиваются пациенты с ППРС, отмечено существенное снижение качества жизни данной группы больных.

Published
2018

3. [Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation]

Author

K Z, Bakhtiiarova, O V, Bragina, Ia V, Vlasov, I V, Greshnova, E P, Evdoshenko, E I, Ivanishenkova, E I, Kairbekova, E N, Karnaukhova, N A, Korotkevich, A V, Leliukhina, I S, Protasov, E V, Rybina, A I, Sazhnev, A A, Skoromets, O A, Soldatova, Iu V, Trinitatskiĭ, A S, Fedianin, S N, Chelnokova, V D, Shabanova, R R, Sharipova, E A, Shchegol'kova, and I A, Iampol'skaia-Gosteva

Subjects
Adult, Male, Adolescent, Middle Aged, Russia, Young Adult, Multiple Sclerosis, Relapsing-Remitting, Treatment Outcome, Humans, Female, Prospective Studies, Biosimilar Pharmaceuticals, Interferon beta-1a, Retrospective Studies
Abstract

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system. Nowadays some disease-modifying drugs (DMD) in the Russian Federation (RF) are biosimilars. Their full spectrum of tolerability and efficacy is to be determined. Here we present results of two retrospective-prospective studies on efficacy and safety of a biosimilar interferon beta-1a (genfaxon) in treatment of MS in the RF.determination of safety and efficacy profile of genfaxon in a routine neurological practice in the RF.Trials were performed in 18 MS centers in the RF. A total of 649 patients aged from 18 to 68 years with the EDSS score no more than 6.0 were treated with genfaxon for 12 months. The first group was comprised of 'naïve' patients without previous history of DMD administration. There were patients in the second group which have already received some of DMD. Statistical analysis was performed with the help of significance criteria (χ-square), t-criteria of Student for analysis of independent samplings.There were no serious adverse events during the period of the study. "Naïve" patients had significantly lower number of adverse events, than patients with previous history of DMD usage. Efficacy results were comparable with results published for the Rebif.Data, received from the studies show equal efficacy and tolerability of genfaxon compared with original DMD Rebif.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results